IRVINE, Calif.--(BUSINESS WIRE)--April 6, 2006--Allergan, Inc. (NYSE:AGN - News) today announced the pricing of the concurrent private placements of $700 million aggregate principal amount of 1.50% Convertible Senior Notes due 2026 (or $750 million aggregate principal amount if the initial purchasers exercise their over-allotment option in full), and $800 million aggregate principal amount of 5.75% Senior Notes due 2016. Allergan estimates that the net proceeds from these offerings will be approximately $1.48 billion after deducting discounts, commissions and estimated expenses (or $1.53 billion if the initial purchasers exercise their over-allotment option in full). The Convertible Senior Notes are being sold in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933 and the Senior Notes are being sold in a private placement to qualified institutional buyers and non-U.S. persons pursuant to Rule 144A and Regulation S under the Securities Act of 1933.
